DARE vs. ATOS, CRBP, CLYM, ZURA, ANIX, CRDL, XBIT, MGX, ELUT, and ALTS
Should you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Atossa Therapeutics (ATOS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), Zura Bio (ZURA), Anixa Biosciences (ANIX), Cardiol Therapeutics (CRDL), XBiotech (XBIT), Metagenomi (MGX), Elutia (ELUT), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry.
Daré Bioscience vs.
Atossa Therapeutics (NASDAQ:ATOS) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
Atossa Therapeutics has higher earnings, but lower revenue than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than Atossa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Atossa Therapeutics has a net margin of 0.00% compared to Daré Bioscience's net margin of -191.65%. Daré Bioscience's return on equity of 0.00% beat Atossa Therapeutics' return on equity.
In the previous week, Atossa Therapeutics and Atossa Therapeutics both had 1 articles in the media. Atossa Therapeutics' average media sentiment score of 1.94 beat Daré Bioscience's score of 0.22 indicating that Atossa Therapeutics is being referred to more favorably in the media.
Atossa Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.
Daré Bioscience received 117 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. Likewise, 73.31% of users gave Daré Bioscience an outperform vote while only 65.22% of users gave Atossa Therapeutics an outperform vote.
Atossa Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 780.28%. Daré Bioscience has a consensus target price of $24.00, indicating a potential upside of 657.10%. Given Atossa Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Atossa Therapeutics is more favorable than Daré Bioscience.
12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are held by institutional investors. 7.6% of Atossa Therapeutics shares are held by insiders. Comparatively, 4.0% of Daré Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Atossa Therapeutics beats Daré Bioscience on 10 of the 16 factors compared between the two stocks.
Get Daré Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Daré Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:DARE) was last updated on 2/22/2025 by MarketBeat.com Staff
Free DARE Stock Alerts